Guest Editor(s)
-
- Dr. Barry R. Davies
- Early Oncology, AstraZeneca R&D, Cambridge, UK.
Website | E-mail
-
- Dr. Tim Fenton
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Website | E-mail
-
- Prof. Michelle Garrett
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Website | E-mail
-
- Prof. Martin Michaelis
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Website | E-mail
-
- Dr. Mark Wass
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Website | E-mail
Special Issue Introduction
Despite substantial improvements in recent decades, the prognosis for those cancer patients who suffer from metastatic disease and depend on systemic drug therapy remains unsatisfactorily poor. Both intrinsic resistance and the formation of acquired drug resistance substantially affect the efficacy of cancer drugs. The advancement of precision therapy, in particular the development of improved methods to analyse liquid biopsies, holds promise for improved monitoring of the tumour response and the effective guidance of therapies to patients that will respond to it. The effective use of liquid biopsies will largely depend on the effective interpretation of 'omics' data. Moreover, functional data from pre-clinical resistance models will be needed to complement clinical data. Hence, a close and intense collaboration is required among pre-clinical researchers, clinicians, and computational biologists to develop more effective anti-cancer therapies. This conference, 2nd BACR Conference "Response and Resistance in Cancer Therapy" (
https://www.bacr.org.uk/event/response-and-resistance-in-cancer-therapy), will bring together and showcase cancer researchers from these areas, who will present and discuss the latest advances in understanding the mechanisms of drug resistance in cancer, the identification of biomarkers of drug sensitivity/resistance and how they can be linked to precision medicine approaches.
Keywords
Cancer drug resistance, prognosis, systemic drug therapy, intrinsic resistance, precision medicine, tumour response, mechanism, bio-marker
Submission Deadline
31 May 2022
Cancer Drug Resistance
